November 12, 2020

RAPID Registry Evaluates Thromboaspiration With AngioDynamics’ AngioVac System

November 12, 2020—AngioDynamics, Inc. announced that the safety and efficacy results from the Registry of AngioVac System Procedures In Detail (RAPID) database, which was designed to evaluate the patterns of use, safety, and efficacy of the AngioVac system in the bulk removal of undesirable intravascular material were presented by principal investigator John Moriarty, MD.

The objective of the registry was to capture data on the use of the AngioVac system for various anatomic locations. Greater than 70% of clot/mass removal was achieved in a majority of the patient population. According to the company, the study confirmed the AngioVac system to be versatile, safe, and effective for the removal of vascular thrombi and cardiac masses across a broad range of patient populations.

Dr. Moriarty shared the findings in a sponsored session at VIVA 2020, the Vascular InterVentional Advances annual meeting held as a virtual congress November 6-8, 2020. Additionally, the company noted that the findings from the RAPID Registry have been accepted for publication in the Journal of Vascular and Interventional Radiology.

The RAPID registry enrolled 234 patients across 21 sites, surpassing its 200-patient enrollment goal. Among enrolled patients, 48.3% had a mass in the right heart, 35.9% had caval thromboemboli, 8.5% had catheter-related thrombi, 1.7% had a pulmonary embolism, and 5.6% had a combination of these.

“Our goal threshold was to remove over 70% of the clot, which we felt was clinically relevant, and each of the three main groups—the caval group, the right heart group, and the catheter associated clot group—were associated with very high rates of clot removal,” commented Dr. Moriarty in the company's announcement. “In the first 2 years of the Registry, there were more caval thrombectomies than right heart mass procedures, and that flipped in the latter 2 years. If we were to extrapolate our trajectory, we would say that close to 70% of all procedures are being performed in the right heart. Additionally, the AngioVac system was successfully tested by a number of different practitioners, including cardiologists, EP cardiologists, cardiac surgeons, vascular surgeons, and interventional radiologists. Ultimately, the diversity of providers, combined with the efficacy and safety results, demonstrates the unique and versatile nature of the AngioVac system.”

AngioDynamics' AngioVac Cannula is indicated for use as a venous drainage cannula and for removal of fresh, soft thrombi or emboli during extracorporeal bypass for up to 6 hours. The AngioVac Circuit is indicated for use in procedures requiring extracorporeal circulatory support for periods of up to 6 hours, noted the company's announcement.


November 12, 2020

Avicenna.AI Provides Cina Head AI Triage Solution for Canon’s Automation Platform

November 10, 2020

HIFLO Trial Evaluates MicroVascular Tissues mVasc Wound Healing Device